Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.
Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies.

Immunovant
Enabling normal lives for patients with autoimmune diseases

Dermavant
Leading innovation in medical dermatology

Genevant
Delivering results through RNA therapeutics

Proteovant
Degrading errant proteins to elevate patient health

Kinevant
Developing a new therapy for sarcoidosis

Hemavant
Exploring novel solutions for blood disorders

Lysovant
Developing a novel endolysin for bacterial infections

Affivant
Developing bispecific antibodies for solid tumors

Aruvant
Developing gene therapies for rare diseases

Lokavant
Shifting the paradigm in clinical trial intelligence

Vant.AI
Expanding the boundaries of in-silico drug design

Datavant
Organizing the world's healthcare data

Cytovant
Developing novel and innovative cellular therapeutics in Asia
Roivant Health is our platform for founding and funding innovative digital health businesses.
As an integrated pharma-tech business, we hope to lead the transition to a more data-driven, patient-centric, and value-oriented health system. Companies we have built include Datavant, now the nation's largest health data ecosystem, and Lokavant, a leading clinical trial intelligence company creating operational transparency for sponsors and CROs.
Partners
We have a diverse pipeline of investigational drugs across our family of companies.
Roivant empowers a global team of innovators in the biopharmaceutical industry to expand the world of treatable conditions.
With offices in New York City, Boston, and Basel as well as remote working options, collaborating on a better future together has never been easier.
Grow With Roivant
Matt Gline
Chief Executive Officer

Eric Venker, MD
President & Chief Operating Officer

Mayukh Sukhatme
President & Chief Investment Officer

Frank Torti, MD
Vant Chair

Srini Ramanathan, PhD
Chief Development Officer

Richard Pulik
Chief Financial Officer

Rakhi Kumar
Chief Accounting Officer

Jo Chen
General Counsel

Woody Sherman, PhD
Chief Computational Scientist

Alex Gasner
EVP, Roivant Health

Matt Maisak
Chief Operating Officer, Roivant Platforms

Pete Salzmann, MD, MBA
CEO, Immunovant

Todd Zavodnick
CEO, Dermavant

Bill Gerhart
CEO, Kinevant

William Chou, MD
CEO, Aruvant

Pete Lutwyche
CEO, Genevant

Drew Fromkin
CEO, Proteovant

Lindsay Androski
CEO, Roivant Social Ventures

Benjamin Zimmer
CEO, Priovant

Rohit Nambisan
CEO, Lokavant

John Xu, MD
President, Cytovant

Bill Macias, MD, PhD
Chief Medical Officer, Immunovant

Chris Chapman
Chief Commercial Officer, Dermavant

Chris Van Tuyl
Chief Legal Officer, Dermavant

Christopher Winter, PhD
Head of Portfolio Strategy, Roivant Discovery

David Rubenstein, MD, PhD
Chief Scientific Officer, Dermavant

Huafeng Xu, PhD
CTO, Roivant Discovery

James Heyes, PhD
Chief Scientific Officer, Genevant

John Alfano
Chief Operating Officer, Lokavant

Julia G. Butchko
Chief Development & Technology Officer, Immunovant

Michael Swartzburg
Chief Financial Officer, Dermavant

Pamela Carroll, PhD
Chief Business Officer, Roivant Discovery

Paul Seaback
Chief Technical Officer, Dermavant

Pete Zorn
Chief Legal Officer, Genevant

Philip Brown, MD, JD
Chief Medical Officer, Dermavant

Matt Gline
Chief Executive Officer

Vivek Ramaswamy
Chairman

Andrew Lo
Director

Patrick Machado
Director

Ilan Oren
Director

Daniel Gold
Director

Masayo Tada
Director

James C. Momtazee
Director

Keith Manchester
Director
Roivant's drug discovery capabilities are driven by our industry-leading computational platform, which combines preeminent physics-based simulation tools with machine learning to generate unprecedented predictive power that can tackle previously intractable challenges.
The tight integration of our computational platform with our broad experimental capabilities and deep drug discovery experience enables the rapid design and optimization of new drugs to address a wide range of targets for diseases with high unmet need.
Learn MoreNEW YORK
Roivant Sciences, Inc.
151 W 42nd Street
15th Floor
New York, NY 10036
United States
BOSTON
Roivant Sciences, Inc.
451 D Street
Boston, MA 02210
United States
BASEL
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland
© 2022 Roivant Sciences Ltd. All rights reserved.
Careers Privacy Policy Terms of Use Legal